Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scorpex, Inc. (SRPX) Taps Major Market Opportunity in Mexico
Mexico, like any country, has its share of internal challenges. But none of that seems to have dimmed the consensus that the country will play an expanding economic role in North America and the world over the next decade. A growing population gives Mexico a demographic profile that a number of industrialized countries would envy. Its economic fundamentals have generally improved over the last 20 years, in spite of the inevitable effects of the current global economic crisis, with industrial development and privatization continuing to expand.
The result of all this has been a growing need for improved waste handling throughout Mexico, and especially in the Baja Peninsula, a popular tourist and agricultural center with its own growing economy.
Scorpex has clearly recognized the possibilities, and is well along the way toward completing a long anticipated and much in demand full service waste disposal and recycling operation near Ensenada along the northwest coast of Baja, only about 25 miles south of Mexico’s border with California. It will be a state-of-the-art facility, able to process all manner of waste, including toxic and hazardous. Scorpex has financed and is set to install a sophisticated waste gasification and thermal oxidation system, and already has more customers lined up than it can handle. But this is just the beginning. The company’s long term plans call for additional facilities, strategically positioned throughout Mexico.
Taking advantage of Mexico’s expanding waste processing market is not a simple process. In addition to having a clear sense of the market, a major strength of Scorpex is its demonstrated ability to build and maintain a strong and positive working relationship with the Mexican government and local communities, which is necessary to obtain all of the required approvals and a discouragement to potential competitors.
SRPX Taps Major Market Opportunity in Mexico
Mexico, like any country, has its share of internal challenges. But none of that seems to have dimmed the consensus that the country will play an expanding economic role in North America and the world over the next decade. A growing population gives Mexico a demographic profile that a number of industrialized countries would envy. Its economic fundamentals have generally improved over the last 20 years, in spite of the inevitable effects of the current global economic crisis, with industrial development and privatization continuing to expand.
The result of all this has been a growing need for improved waste handling throughout Mexico, and especially in the Baja Peninsula, a popular tourist and agricultural center with its own growing economy.
Scorpex has clearly recognized the possibilities, and is well along the way toward completing a long anticipated and much in demand full service waste disposal and recycling operation near Ensenada along the northwest coast of Baja, only about 25 miles south of Mexico’s border with California. It will be a state-of-the-art facility, able to process all manner of waste, including toxic and hazardous. Scorpex has financed and is set to install a sophisticated waste gasification and thermal oxidation system, and already has more customers lined up than it can handle. But this is just the beginning. The company’s long term plans call for additional facilities, strategically positioned throughout Mexico.
Taking advantage of Mexico’s expanding waste processing market is not a simple process. In addition to having a clear sense of the market, a major strength of Scorpex is its demonstrated ability to build and maintain a strong and positive working relationship with the Mexican government and local communities, which is necessary to obtain all of the required approvals and a discouragement to potential competitors.
ON Semiconductor Corp. (ONNN) Receives Home Electronic Product Design 2011 Award for their Energy Efficient, High Precision Mixed-Signal Microcontroller
ON Semiconductor, which wields an impressive manufacturing, design and supply chain infrastructure in energy efficient silicon devices from its corporate HQ in Phoenix, AZ, recently received the Electronic Product Design 2011 e-Legacy Award in Medical Advances for their Q32M210 Precision Mixed-Signal 32-bit Microcontroller.
Built on a rock-solid programmable ARM® Cortex™-M3 processor foundation, the Q32M210 delivers maximum code portability, coupled with a low-noise analog front-end that can be configured for whatever product developers need. When it comes to robust, continuous precision measurement in a portable sensing environment, the Q32M210 sets new standards for tight integration, performance and reliability.
Dual 16-bit ADCs deliver high-fidelity voltage reference and triple 10-bit DACs, meaning vastly lower noise than in competing, linear solutions. On-chip power supervision, redundant flash memory storage (error checking/correction circuitry), a variety of peripheral interfaces for external UIs via USB and many other key features make the Q32M210 salient.
The icing on the cake is the energy efficiency profile, bringing high performance at exceptional power efficiency rates; this design effectively results in an extremely flexible, scalable measurement engine that allows for a range of finely tuned price/performance ratios to be set by developers during deployment operations.
Senior Director, Consumer Health Products for ONNN, Michel De Mey, hailed the clear thumbs up from Electronic Product Design as a true honor, noting that it has always been the goal of the Company to be at the tip of the spear in “shaping the future of the medical electronics industry”. De Mey underscored the tremendous potential for burgeoning end-markets like blood glucose monitoring, wireless ECG, pulse oximeters and other portable sensing equipment, pointing to the Q32M210 as a potential silver bullet.
Indeed the device has wide-ranging applications, even in other, non-medical applications, like home-based displays for energy monitoring or even fitness monitoring devices. By fusing together a solution to the real-world concerns of device power consumption and battery life, with a powerful, high-precision measurement engine, ONNN has earned the recognition Electronic Product Design and developers as well.
For more information on the Q32M210 award and ON Semiconductor, please visit the Company’s website at: www.OnSemi.com
Fuel Tech, Inc. (FTEK) Receives Multiple New Contracts both Foreign and Domestic for Air Pollution Control Projects Totaling $3 Million
Fuel Tech, a world leader in advanced engineering solutions for combustion and emissions control systems for utility and industrial applications, yesterday announced that it has signed several new contracts for air pollution control that total $3.0 million. These contracts were signed with both new and existing clients in the US and abroad.
Two orders were received from Chinese power plants for the ULTRA systems process that safely and cheaply convert urea to ammonia for use as a reagent in the reduction of nitrogen oxide (NOx) thus eliminating the danger associated with the transport, storage, and handling of aqueous ammonia or anhydrous. The largest order is from an existing client to retrofit two large coal units and the second order is for two medium sized coal operations. Equipment should be delivered in late 2011 for both clients.
The new Cross-State Air Pollution Rule, which becomes law in the United States at the start of 2012, drove a major domestic utility company to purchase Fuel Tech’s Selective Non-Catalytic Reduction (SNCR) systems to address NOx emissions at an unnamed power plant. Also, other domestic orders for Computational Fluid Dynamiz (CFD) modeling relate to this new rule and point to future sales.
“We continue to gain traction in the Chinese market, in particular with our proprietary ULTRA technology. China continues to be a very active market for all of our technologies as new regulations are now in place for broad reductions of NOx emissions. Additionally, we are pleased that these domestic utility customers have selected Fuel Tech to implement equipment solutions and evaluate short term strategies to achieve compliance in a dynamic regulatory environment that is calling for greater reductions in NOx emissions under the new Cross-State Air Pollution Rule. Fuel Tech’s SNCR technology can provide our customers with timely NOx reductions where boilers may operate across a wide load range, and these flexible systems are designed to complement additional Fuel Tech NOx reduction technologies, including combustion modifications, ASCR™ (Advanced Selective Catalytic Reduction) and conventional SCR,” said Douglas G. Bailey, Chairman, President and Chief Executive Officer, Fuel Tech in a press release.
For more information, please visit Fuel Tech’s web site at www.ftek.com
We have sent them news in the past and anticipate ongoing coverage.
Unlike other biotech companies, VistaGen has the potential to completely revolutionize the way drugs are developed in the future with their Human Clinical Trials in a Test Tube™ platform. With advances constantly taking place and new applications being discovered, VistaGen provides BioWorld with fresh and very exciting content.
IsoRay, Inc. (ISR) Radiation Technology used in World’s First Treatment of Metastasized Brain Cancer
Medical technology company IsoRay today announced that doctors at New York Presbyterian Hospital/ Weill Cornell Medical Center have performed the world’s first treatment of metastasized brain cancer using IsoRay’s Cesium-131 brachytherapy (internal radiation therapy) seeds, which previously received FDA clearance for the treatment of various cancers.
Treatment of metastasized cancers, which are cancers that spread from the site of the original tumor, is IsoRay’s latest application of pioneering brachytherapy treatment, representing milestone advancement in internal radiation therapy.
Doctors at the Medical Center implanted the seeds directly into a woman’s brain to treat a cancer that had originated in the breast.
Brain cancer treatment often involves removal of the brain tumor and weeks of recovery before external beam radiation treatment can begin. This time gap can increase the chance of tumor recurrence. New York Presbyterian Radiation Oncologist Dr. A. Gabriella Wernicke, M.D., M.Sc., said Cesium-131 is an important alternative because it gives doctors the opportunity to act immediately.
Cesium-131 offers several other benefits over current alternatives, including the advantage that it does not require weeks of follow-on treatment necessary with traditional external beam radiation, which involves numerous return trips to the hospital. IsoRay said Cesium-131 seeds offer rapid and aggressive delivery of radiation compared to other types of internal, low dose rate radiation and limit damage to healthy surrounding tissues and organs, directly impacting longevity and the potential of recurrence.
“The thought leaders at New York Presbyterian Hospital/Weill Cornell Medical Center were among the early adopters of Cesium-131 because they were quick to recognize the important advantages Cesium-131 offers patients. I strongly believe that adoption of Cesium-131 for the treatment of primary and metastasized cancers will continue growing at an increasing rate as the medical community becomes aware of the significant advantages it offers in treating cancer sites throughout the body,” IsoRay CEO Dwight Babcock stated.
Since the successful treatment of the first patient, doctors at New York Presbyterian/Weill Cornell Medical Center used IsoRay’s patented Cesium-131 brachytherapy seeds to treat more than 20 other patients with recurrent Glioblastomas, as well as metastasized brain cancer.
For more information visit www.isoray.com
American Superconductor (AMSC) Highlights Key Achievements supporting Global Reach
Global power technologies company American Superconductor Corp. recently issued an update on its recent performance and accomplishments in the wind power and power grid markets, including its achievement of nearly $100 million in new contracts since the start of the company’s fiscal year on April 1, 2011.
Since the beginning of April, the company has signed contracts with wind turbine manufacturers in China, India and Korea. It has also received orders for its grid interconnection and high voltage stability solutions in the U.S. and Europe, reflecting its global market reach.
“We are pleased to announce these key accomplishments across the Americas, Europe and Asia and our Wind and Grid solutions,” AMSC president and CEO Daniel McGahn stated in the press release. “Through our best-in-class wind turbine designs, superior electrical control systems, and highly efficient transmission and distribution products, AMSC solutions are serving as a catalyst for customer success and providing cleaner, smarter and more efficient energy for the world.”
In China, AMSC inked a multi-year deal to deliver wind turbine ECS to a subsidiary of state-owned Beijing JINGCHENG Machinery Electric Holding Co. Ltd, which AMSC plans to ship from late 2011 through 2014.
In India, the company signed a contract to deliver wind turbine ECS to Inox Wind Ltd., with shipments expected to begin in late 2011 and run through 2012.
AMCS also signed a contract in South Korea, in which the company will provide wind turbine core electrical components to Hyundai Heavy Industries (HHI) later this year.
AMSC’s Grid solutions allow for the developers of wind farm and solar power plant to integrate renewable power into the grid and allow electric utilities to optimize their transmission and distribution networks.
In this arena, AMSC signed a multi-million dollar contract to provide a D-VAR® system for Keys Energy Services, a public power utility in Florida.
The company also inked several new grid integration solution contracts in Europe, related to wind farms and solar power plants; in this instance, AMSC will integrate more than 150 MW of renewable energy into the grid.
In South Korea, AMSC made its first Amperium™ wire shipment to LS Cable & System under a multi-year supply agreement announced in October 2010.
For more information visit www.amsc.com
VistaGen Therapeutics, Inc. (VSTA) Announces Significant Progression in its Pancreatic Cell and Regenerative Medicine Programs
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, just announced the publication of its original research demonstrating the use of pluripotent stem cells to generate insulin in mice. The studies are part of VistaGen’s Human Clinical Trials in a Test Tube(TM) platform which has proprietary applications in drug screening, cell therapy, and regenerative medicine in the areas of metabolic disease and diabetes.
The research, titled Pdx1 and Ngn3 Overexpression Enhances Pancreatic Differentiation of Mouse ES Cell-Derived Endoderm Population, originated from a collaboration between VistaGen and the laboratories of Dr. Gordon Keller at the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto and Dr. Atsushi Kubo at Nara Medical University in Japan. It was published in the peer-reviewed journal, PLoS ONE 6(9): e24058, doi: 10.1371/journal.pone.0024058 on September 13, 2011.
Dr. Ralph Snodgrass, President and Chief Scientific Officer of VistaGen, stated, “In addition to presenting a powerful in vitro model system designed to screen for potential genes or drug candidates capable of inducing the production of insulin-secreting pancreatic beta-islet cells, these research results represent another important step towards our goal of developing superior biological systems for drug development. We are grateful for the scientific contributions of our international collaborators to the research reported in this publication, as well as the continuing technical progress we are making through our ongoing and active partnership with Dr. Gordon Keller and his laboratory in Toronto.”
VistaGen has a strong history of successfully advancing its internal commercially-focused research and development programs through collaborations that strategically combine the complementary capabilities of its industry leading scientists with academic leaders in the field of stem cell research. The published results are the consummation of a close and productive international collaboration initiated and led by VistaGen scientists.
The stem cell-derived pancreatic cells developed by the international research team demonstrated the ability to produce and correctly process insulin and secrete C-peptide, characteristics of mature beta-islet cells. In addition, these studies suggest a potential purification or enrichment strategy for beta-islet cell production, facilitating a strategy for the production of large numbers of beta-islet cells for multiple applications. They also point to additional areas for future development as well as provide a strong foundation that supports VistaGen’s efforts to produce fully functional human beta-islet cells for drug discovery and clinical applications.
Multimedia Games Holding Company, Inc. (MGAM) Granted Licenses by Nevada Gaming Commission for Slot Machines in Largest Gaming Market
Multimedia Games Inc., a subsidiary of Multimedia Games Holding Company Inc., announced that the Nevada Gaming Commission has approved manufacturer’s and distributor’s licenses for the company, moving them one step closer to selling and/or leasing slot machines in the State of Nevada. Multimedia is on track to have its first sales and placement of slot machines in Nevada around October 2012. The last hurdle is that the Nevada State Gaming Control Board’s Technology Division needs to review and approve the MForce (TM) platform used by Multimedia Games.
Nevada has about 187,000 slot machines in facilities around the state making it the largest gaming market in North America. There is one operating slot machine in Las Vegas for every 8 residents.
“We appreciate the efforts of both the Nevada Gaming Commission and the Nevada State Gaming Control Board for their consideration and approval of our license application. Since the beginning of fiscal 2010, we have secured over 67 new licenses, and we are particularly pleased to now be licensed in Nevada the largest gaming market in North America,” said Patrick Ramsey, president and CEO, Multimedia Games in a press release on Friday from their Austin headquarters. “We look forward to offering games on our new operating platform to customers in Nevada following the required evaluation and approval process. We believe our games will provide slot players with new, unique entertainment experiences while delivering an attractive return on investment to casino operators.”
Since 1991, Multimedia Games has developed electronic gambling devices for American Indian gaming markets, commercial casinos, charity and international bingo markets. Multimedia also supplies the technology for the video lottery terminals installed at New York State Raceways. Last month the company posted a $2.7 million profit on $33.3 million in revenue for the third quarter ending June 30. In May the company reported a $1.2 million second-quarter profit versus a $5.6 million loss during the same period last year.
For more information on Multimedia Games, please visit www.multimediagames.com
Platinum LTG VII is a large fund that has invested over $5.5 million in VistaGen, with the first investment taking place in 2007. They have been loyal to the company, not selling a single share.
CEO Shawn Singh does not own any percentage of this fund and has never had any affiliation with the fund at any point in the past.
Published Seeking Alpha Article
VistaGen Therapeutics' Potential Rewards Far Exceed Its Current Market Valuation
http://seekingalpha.com/article/295869-vistagen-therapeutics-potential-rewards-far-exceed-its-current-market-valuation
VistaGen Therapeutics, Inc. (VSTA) Announces Significant Progression in its Pancreatic Cell and Regenerative Medicine Programs
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, just announced the publication of its original research demonstrating the use of pluripotent stem cells to generate insulin in mice. The studies are part of VistaGen’s Human Clinical Trials in a Test Tube(TM) platform which has proprietary applications in drug screening, cell therapy, and regenerative medicine in the areas of metabolic disease and diabetes.
The research, titled Pdx1 and Ngn3 Overexpression Enhances Pancreatic Differentiation of Mouse ES Cell-Derived Endoderm Population, originated from a collaboration between VistaGen and the laboratories of Dr. Gordon Keller at the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto and Dr. Atsushi Kubo at Nara Medical University in Japan. It was published in the peer-reviewed journal, PLoS ONE 6(9): e24058, doi: 10.1371/journal.pone.0024058 on September 13, 2011.
Dr. Ralph Snodgrass, President and Chief Scientific Officer of VistaGen, stated, “In addition to presenting a powerful in vitro model system designed to screen for potential genes or drug candidates capable of inducing the production of insulin-secreting pancreatic beta-islet cells, these research results represent another important step towards our goal of developing superior biological systems for drug development. We are grateful for the scientific contributions of our international collaborators to the research reported in this publication, as well as the continuing technical progress we are making through our ongoing and active partnership with Dr. Gordon Keller and his laboratory in Toronto.”
VistaGen has a strong history of successfully advancing its internal commercially-focused research and development programs through collaborations that strategically combine the complementary capabilities of its industry leading scientists with academic leaders in the field of stem cell research. The published results are the consummation of a close and productive international collaboration initiated and led by VistaGen scientists.
The stem cell-derived pancreatic cells developed by the international research team demonstrated the ability to produce and correctly process insulin and secrete C-peptide, characteristics of mature beta-islet cells. In addition, these studies suggest a potential purification or enrichment strategy for beta-islet cell production, facilitating a strategy for the production of large numbers of beta-islet cells for multiple applications. They also point to additional areas for future development as well as provide a strong foundation that supports VistaGen’s efforts to produce fully functional human beta-islet cells for drug discovery and clinical applications.
VSTA Announces Significant Progression in its Pancreatic Cell and Regenerative Medicine Programs
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, just announced the publication of its original research demonstrating the use of pluripotent stem cells to generate insulin in mice. The studies are part of VistaGen’s Human Clinical Trials in a Test Tube(TM) platform which has proprietary applications in drug screening, cell therapy, and regenerative medicine in the areas of metabolic disease and diabetes.
The research, titled Pdx1 and Ngn3 Overexpression Enhances Pancreatic Differentiation of Mouse ES Cell-Derived Endoderm Population, originated from a collaboration between VistaGen and the laboratories of Dr. Gordon Keller at the University Health Network’s McEwen Centre for Regenerative Medicine in Toronto and Dr. Atsushi Kubo at Nara Medical University in Japan. It was published in the peer-reviewed journal, PLoS ONE 6(9): e24058, doi: 10.1371/journal.pone.0024058 on September 13, 2011.
Dr. Ralph Snodgrass, President and Chief Scientific Officer of VistaGen, stated, “In addition to presenting a powerful in vitro model system designed to screen for potential genes or drug candidates capable of inducing the production of insulin-secreting pancreatic beta-islet cells, these research results represent another important step towards our goal of developing superior biological systems for drug development. We are grateful for the scientific contributions of our international collaborators to the research reported in this publication, as well as the continuing technical progress we are making through our ongoing and active partnership with Dr. Gordon Keller and his laboratory in Toronto.”
VistaGen has a strong history of successfully advancing its internal commercially-focused research and development programs through collaborations that strategically combine the complementary capabilities of its industry leading scientists with academic leaders in the field of stem cell research. The published results are the consummation of a close and productive international collaboration initiated and led by VistaGen scientists.
The stem cell-derived pancreatic cells developed by the international research team demonstrated the ability to produce and correctly process insulin and secrete C-peptide, characteristics of mature beta-islet cells. In addition, these studies suggest a potential purification or enrichment strategy for beta-islet cell production, facilitating a strategy for the production of large numbers of beta-islet cells for multiple applications. They also point to additional areas for future development as well as provide a strong foundation that supports VistaGen’s efforts to produce fully functional human beta-islet cells for drug discovery and clinical applications.
Mr. Singh is not affiliated, directly or indirectly, with Platinum LTG VII or any other Platinum family fund.
As of May 11, 2011, Mr. Singh beneficially owned 759,545 shares of the Issuer's Common Stock (including unexercised options and warrants to purchase shares of the Issuer's Common Stock). The shares beneficially owned by Mr. Singh represented 9.15% of the issuer's outstanding shares of Common Stock, as of May 11, 2011.
VistaGen Therapeutics Inc. (VSTA) Leadership Eyes Huge Financial Impact of Stem Cell Developments
When VistaGen Therapeutics announced the appointment of Shawn K. Singh as its CEO, Mr. Singh’s reputation and familiarity with the company had already been established. As Managing Principal of Cato BioVentures, VistaGen’s biggest institutional stockholder, and part-time President of VistaGen, he already knew VistaGen, its goals and its potential.
VistaGen, a South San Francisco based biotech company, is using pluripotent stem cell technologies to develop a new generation of cost-effective, clinically-relevant drug screening systems, offering the possibility of identifying potential toxicity issues early in the drug development process, well before massive amounts of money are lost in developing a drug that is later determined to be toxic to the human heart. It also means that promising new drugs currently shelved because of heart safety concerns can now be economically re-investigated for safer variants, potentially resulting in highly profitable new therapies that would otherwise never make it to market.
The financial potential of VistaGen’s stem cell technology was not lost on Singh, who began his career as a corporate finance attorney in Silicon Valley, and went on to serve in key executive positions with other successful biopharmaceutical and medical device companies, in addition to his tenure as a venture capitalist focused on the biotechnology sector. The possibility of using leading-edge stem cell biology to leverage and potentially recover billions of dollars previously invested by the pharmaceutical industry and thought to be lost in the development of now shelved drugs is too big for the industry to ignore.
VistaGen’s founder, H. Ralph Snodgrass, a Ph.D., is a recognized expert in pioneering stem cell research. Dr. Snodrass has extensive research experience as a professor at the Lineberger Comprehensive Cancer Center in North Carolina, and as a member of the Institute for Immunology in Switzerland. He is a past board member of the Emerging Company Section of the Biotechnology Industry Organization, and has many years of experience in the use of stem cells as biological tools for drug discovery and development. Dr. Snodgrass now serves as VistaGen’s President and Chief Scientific Officer, driving the company’s technical progress.
For additional information, visit the company’s website at www.VistaGen.com
SORL Auto Parts, Inc. (SORL) Creates European Subsidiary to Win More Security Related Auto Parts Contracts with Truck, Bus and Trailer Manufacturers across Europe
SORL Auto Parts, Inc., a leading Chinese supplier of brake and control systems to the global commercial vehicle industry, announced today the creation of a new subsidiary, SORL Europe, to win more contracts and service customers in Europe, Middle East and Africa. SORL Europe will market its quality certified products to truck, trailer and bus manufacturers and look to increase its aftermarket distribution network. The new subsidiary will be located in Brussels, Belgium and will be headed by Jean Francois Barth, Vice President of International Markets and Managing Director SORL.
SORL Auto Parts principally manufactures and distributes automotive brake systems and other key security related auto parts directly to automotive original equipment manufacturers. The Company’s products primarily are used in commercial vehicles like trucks and buses. It is China’s largest commercial airbrake system manufacturer with over half of its customers comprised of China’s major vehicle manufacturers. The European brake market is posed to be an important vehicle for growth with 10 percent growth projected this year for aftermarket products.
“We believe there is a significant opportunity for SORL to expand its presence in these growing markets. The European truck market is particularly attractive as heavy-duty truck registrations increased over 50% in the first half of 2011 and the aftermarket consists of a large number of trucks between 4 and 9 years of service requiring replacement parts. Our product development strategy is focused on providing high-value solutions that increase driver safety. SORL is the best value brand for these markets providing the high-quality products and services our customers expect,” said Jean Francois Barth, Vice President of International Markets and Managing Director.
“SORL Europe is another step in our global expansion. SORL now has dedicated regional operations to enhance our penetration of these important markets. A more local presence will enable us to become more integrated with our customers so we can better anticipate their future requirements. We continue to design and manufacture our products to meet global standards so we can more quickly access and service foreign markets,” added Xiaoping Zhang, Chairman of the Board of Directors and Chief Executive Officer.
BioLineRx Ltd. (BLRX) to Retain KCSA Strategic Communications
Located in Jerusalem, BioLineRx is a publicly-traded company focused on building a portfolio of products for unmet medical needs or with advantages over currently available therapies. Today, BioLineRx took a major step towards prominence with the announcement they have retained KCSA Strategic Communications to direct their U.S. investor relations program.
KCSA is a leading New York-based communications firm that intends to deploy a comprehensive investor relations program with the goal of expanding the influence BioLineRx has within the United States.
Todd Fromer, whom is a Managing Partner of KCSA will lead the KCSA team and provide strategic counsel on financial communication matters. In reference to KCSA being retained by BioLine Rx, Fromer stated, “Since listing its ADR’s on the NASDAQ in July, BioLineRx has had little exposure to the U.S. investment community. As such, we believe there is a tremendous opportunity for us to broaden awareness among investors and highlight the opportunity BioLineRx and its products provide. As part of our program, we will work with the BioLineRx management team to effectively and regularly communicate with its U.S. investor base.”
BioLine Rx CEO Dr. Kinneret Savitsky commented, “I am excited to begin working with KCSA in order to create greater awareness of BioLineRx in the U.S. investment community. We have several exciting products in our pipeline that are in advanced stage clinical trials, providing us with significant short-term and long-term opportunities to grow our business. With KCSA’s proactive communications program, we hope to highlight the ongoing development of these products to our shareholders and potential value of these products upon receiving regulatory market clearance.”
Currently, BioLineRx is trading in the $3.49 range. To learn more about the company as a whole, visit their website at: www.biolinerx.com
VistaGen Therapeutics Inc. (VSTA) Leadership Eyes Huge Financial Impact of Stem Cell Developments
When VistaGen Therapeutics announced the appointment of Shawn K. Singh as its CEO, Mr. Singh’s reputation and familiarity with the company had already been established. As Managing Principal of Cato BioVentures, VistaGen’s biggest institutional stockholder, and part-time President of VistaGen, he already knew VistaGen, its goals and its potential.
VistaGen, a South San Francisco based biotech company, is using pluripotent stem cell technologies to develop a new generation of cost-effective, clinically-relevant drug screening systems, offering the possibility of identifying potential toxicity issues early in the drug development process, well before massive amounts of money are lost in developing a drug that is later determined to be toxic to the human heart. It also means that promising new drugs currently shelved because of heart safety concerns can now be economically re-investigated for safer variants, potentially resulting in highly profitable new therapies that would otherwise never make it to market.
The financial potential of VistaGen’s stem cell technology was not lost on Singh, who began his career as a corporate finance attorney in Silicon Valley, and went on to serve in key executive positions with other successful biopharmaceutical and medical device companies, in addition to his tenure as a venture capitalist focused on the biotechnology sector. The possibility of using leading-edge stem cell biology to leverage and potentially recover billions of dollars previously invested by the pharmaceutical industry and thought to be lost in the development of now shelved drugs is too big for the industry to ignore.
VistaGen’s founder, H. Ralph Snodgrass, a Ph.D., is a recognized expert in pioneering stem cell research. Dr. Snodrass has extensive research experience as a professor at the Lineberger Comprehensive Cancer Center in North Carolina, and as a member of the Institute for Immunology in Switzerland. He is a past board member of the Emerging Company Section of the Biotechnology Industry Organization, and has many years of experience in the use of stem cells as biological tools for drug discovery and development. Dr. Snodgrass now serves as VistaGen’s President and Chief Scientific Officer, driving the company’s technical progress.
VSTA Leadership Eyes Huge Financial Impact of Stem Cell Developments
When VistaGen Therapeutics announced the appointment of Shawn K. Singh as its CEO, Mr. Singh’s reputation and familiarity with the company had already been established. As Managing Principal of Cato BioVentures, VistaGen’s biggest institutional stockholder, and part-time President of VistaGen, he already knew VistaGen, its goals and its potential.
VistaGen, a South San Francisco based biotech company, is using pluripotent stem cell technologies to develop a new generation of cost-effective, clinically-relevant drug screening systems, offering the possibility of identifying potential toxicity issues early in the drug development process, well before massive amounts of money are lost in developing a drug that is later determined to be toxic to the human heart. It also means that promising new drugs currently shelved because of heart safety concerns can now be economically re-investigated for safer variants, potentially resulting in highly profitable new therapies that would otherwise never make it to market.
The financial potential of VistaGen’s stem cell technology was not lost on Singh, who began his career as a corporate finance attorney in Silicon Valley, and went on to serve in key executive positions with other successful biopharmaceutical and medical device companies, in addition to his tenure as a venture capitalist focused on the biotechnology sector. The possibility of using leading-edge stem cell biology to leverage and potentially recover billions of dollars previously invested by the pharmaceutical industry and thought to be lost in the development of now shelved drugs is too big for the industry to ignore.
VistaGen’s founder, H. Ralph Snodgrass, a Ph.D., is a recognized expert in pioneering stem cell research. Dr. Snodrass has extensive research experience as a professor at the Lineberger Comprehensive Cancer Center in North Carolina, and as a member of the Institute for Immunology in Switzerland. He is a past board member of the Emerging Company Section of the Biotechnology Industry Organization, and has many years of experience in the use of stem cells as biological tools for drug discovery and development. Dr. Snodgrass now serves as VistaGen’s President and Chief Scientific Officer, driving the company’s technical progress.
Apple, Inc. (AAPL) Remains Silent on iPod Lineup
The iPod saved Apple and revolutionized the music industry, while making investors happy as shares have surged a split-adjusted 4,562% since the music player made its debut on Oct. 23, 2001. However, its glory days may be over. Although more than 45 million iPods have been sold over the last four quarters alone, the 10th anniversary is approaching and there are signs that Apple is shifting more of its focus elsewhere.
The number of iPods that continue to sell are astounding, but sales are in decline. Unit sales are down 12.5% year-over-year and revenues have fallen 6.2%. Notably, Apple has been unusually quiet about their highly successful product line this year. We’re nearing the end of September and still there has not been a word from the company.
Yesterday reports emerged of an Apple event scheduled for October 4, but that the main focus would be on the iPhone, not the iPod lineup. Apple is not likely to build an event around a product that’s in retreat, even if it’s historically the most successful. The silence surrounding the iPod, combined with the fact that Apple didn’t unveil a new version of the iPhone at its developers’ conference in June, has added to the feeling that Apple will use whatever event is coming up to make the iPhone the star of its next show.
“This is Steve Jobs’s genius,” said Silicon Valley futurist thinker and Stanford University instructor Paul Saffo. “The guy destroys the industries he creates to create something new. Who else but Jobs would invent the whole music model with the stand-alone player, and then destroy the market for a stand-alone player by coming out with a phone and a pad?”
Like other industry changers, such as the personal computer and television, the iPod isn’t going away. Don’t forget there is an iPod application in every Apple iPhone and iPad. But even though the iPod will remain on Apple’s roster, it is obvious that after 10 years, its days in the starting lineup as a standalone player are done.
New video posted on VistaGen Website
http://www.vistagen.com/?page_id=26
Spontaneously and rhythmically beating engineered human heart tissue from pluripotent stem cells
Archived Press Releases
September 14, 2011
VistaGen Therapeutics Provides Investor Update On Corporate Activities and Upcoming Initiatives
http://www.vistagen.com/?p=233
May 17, 2011
VistaGen Therapeutics and Excaliber Enterprises Announce Completion of Reverse Merger and $3.8 Million Financing
http://www.vistagen.com/?p=58
January 12, 2011
VistaGen Therapeutics and NuPotential Receives NIH Grant to Develop Safer Approaches for Producing Patient-specific Induced Pluripotent Stem Cells
http://www.vistagen.com/?p=72
December 22, 2010
VistaGen Therapeutics Announces Successful Completion of Initial Phase 1 Safety Study of AV-101 for Neuropathic Pain
http://www.vistagen.com/?p=150
August 20, 2009
VistaGen Appoints Industry Veteran Shawn Singh as Chief Executive Officer
http://www.vistagen.com/?p=152
January 15, 2009
VistaGen and Capsant Sign Strategic Stem Cell Technology Commercialization Agreement
http://www.vistagen.com/?p=154
December 18, 2008
VistaGen and WARF Sign License Agreement for Human Embryonic Stem Cell Technology
http://www.vistagen.com/?p=156
December 16, 2008
VistaGen Receives Significant Stem Cell Tools and Technologies Grant from California Institute for Regenerative Medicine
http://www.vistagen.com/?p=158
October 16, 2008
VistaGen Team Pinpoints Key Biochemical Pathways Involved in Generating ES cell-derived Heart Cells
http://www.vistagen.com/?p=160
June 17, 2008
New Broad Composition of Matter Patent Protects VistaGen’s ES Cell Applications
http://www.vistagen.com/?p=162
May 22, 2008
VistaGen Licenses Customized Stem Cell-Based Drug Discovery Assays to Sanwa, a Japanese Pharmaceutical Company
http://www.vistagen.com/?p=164
April 23, 2008
VistaGen Collaborates with Canadian, U.S., and British Researchers ToIsolate Earliest Embryonic Stem Cell-Derived Human Cardiac Cell
http://www.vistagen.com/?p=166
March 12, 2008
VistaGen Therapeutics Announces Broad Stem Cell R&D Alliance With Toronto’s University Health Network and The McEwen Centre For Regenerative Medicine
http://www.vistagen.com/?p=168
November 23, 2007
VistaGen Sees Promise for Stem Cell ‘Breakthrough’ to Accelerate Drug Discoveryand Development
http://www.vistagen.com/?p=170
November 12, 2007
VistaGen Publishes Preclinical Data Supporting the Therapeutic Potential of AV-101 for Parkinson’s Disease — Company’s Lead Compound Can Stimulate Dopaminergic Neuron Activity —
http://www.vistagen.com/?p=172
November 6, 2007
VistaGen Awarded $1.2 Million from NIH for Development of AV-101 for Neuropathic Pain, Parkinson’s Disease and Epilepsy
http://www.vistagen.com/?p=174
January 30, 2007
VistaGen’s AV-101 Drug Candidate Yields Positive Preclinical Data for Neuropathic Pain Applications– IND to be Submitted to FDA in 2007 —
http://www.vistagen.com/?p=176
December 21, 2006
VistaGen Therapeutics Announces 3 Significant Publications Supporting the Use of Embryonic Stem Cells for Drug Discovery and Development
http://www.vistagen.com/?p=178
December 7, 2006
VistaGen Therapeutics Announces Positive AV-101 Preclinical Data Suggesting Potential for Parkinson’s Disease
http://www.vistagen.com/?p=181
November 30, 2006
VistaGen Therapeutics and Sanwa Renew Embryonic Stem Cell Drug Discovery and Development Partnership Focused on New Diabetes Treatments
http://www.vistagen.com/?p=184
March 23, 2006
VistaGen Therapeutics and CATO BioVentures Sign Strategic Business Development Agreement for CNS Products
http://www.vistagen.com/?p=186
August 23, 2005
Lantos Affirms Support of Expanded Stem Cell Research–Applauds Commitmentby VistaGen Employees and Investors
http://www.vistagen.com/?p=188
August 11, 2005
VistaGen Therapeutics Secures Development Support for New Drug Candidate for Huntington’s Disease
http://www.vistagen.com/?p=190
July 12, 2005
VistaGen Therapeutics Awarded $197,000 NIH Grant for Expanded Preclinical Development of New Drug Candidate for Neuropathic Pain
http://www.vistagen.com/?p=192
May 24, 2005
VistaGen Therapeutics Awarded $3,700,000 NIH Drug Development Grant for Lead Epilepsy Drug Candidate
http://www.vistagen.com/?p=194
Pearl Stream Implements QAD, Inc. (QADA) Enterprise Application to Support Boost in Plant Production
QAD Inc., a leading provider of enterprise software and services for global manufacturing companies, today announced that German-Korean-owned Pearl Stream, an electronic components manufacturer, has implemented QAD Enterprise Applications as part of the recent roll-out of its new plant in Poland.
Founded earlier this year, Pearl Stream’s plant began production in April, manufacturing more than 10,000 electronics components per day, for use in televisions, home appliances and the automotive market.
Pearl Stream began implementing QAD Enterprise Applications to support its aggressive production targets as part of its two-phased deployment strategy. The company said it chose QAD’s system for its scalability, rapid deployment capabilities and strong manufacturing focus.
“We had only four months to build a factory and start production. Selecting the right ERP provider was critical to minimizing our risk and maximizing our workflow, quickly,” Krzysztof Jarzyna, plant manager at Pearl Stream stated in the press release. “QAD Enterprise Applications meets our expectations perfectly. It is a transparent and easy-to-use system. We are convinced it will contribute to the success and further development of our company.”
The first phase of Pearl Stream’s two-phased deployment strategy utilized QAD modules as a means to support its business and management processes, as well as for purchasing, finance, inventory management and distribution.
Phase two of the strategy was completed in mid-July 2011 with the deployment of QAD Manufacturing. Pearl Stream says it is now properly positioned to increase production.
For more information visit www.qad.com
Investors looking for recent press releases issued before the company became publicly traded should visit VistaGen's website at http://www.vistagen.com
Select the "Press Releases" tab at the top of the page. As noted before, this company isn't an early-stage concept. VistaGen is advancing quickly to capitalize on multiple large market opportunities.
More information on the company can be found at http://vsta.missionir.com
Gentium (GENT) Posts Q2, HY 2011 Financial Results
Gentium S.p.A., an Italy-based biopharmaceutical company, yesterday reported financial results for the first half of 2011 and the quarter ended June 30, 2011. The company’s financial statements are prepared using the Euro as its functional currency as of June 30, 2011: EUR 1.00 = $1.44.
For the second quarter ended June 30, 2011, the company reported total revenues of EUR 6.72 million compared with EUR 7.55 million for the same period in 2010.
Operating costs and expenses for the second quarter 2011 were EUR 5.52 million compared with EUR 5.37 million reported for the second quarter of the year prior.
Gentium reported operating income of EUR 1.20 million for the second quarter of 2011 compared with EUR 2.17 million for the comparable quarter of last year.
Net income for the second quarter was EUR 0.97 million, or basic and diluted net income per share of EUR 0.07 and EUR 0.06, respectively, compared with EUR 2.35 million in the second quarter of 2010.
As of June 30, 2011, Gentium had cash and cash equivalents of EUR 9.83 million compared to EUR 8.74 million at December 31, 2010.
For the first half of 2011, Gentium reported total revenues of EUR 12.77 million compared to EUR 12.53 million in the first half of 2010.
Operating costs and expenses for the first six months of 2011 were EUR 9.69 million compared to EUR 10.47 million reported for the comparable period of 2010. The company noted that operating costs and expenses for the prior-year period include a one-time restructuring charge of EUR 0.95 million.
Operating income for the first half of 2011 was EUR 3.08 million compared to EUR 2.06 million reported in the first half of 2010.
Gentium reported net income for the period at EUR 2.67 million, or basic and diluted net income per share of EUR 0.17 and EUR 0.18 per share, respectively, compared to EUR 2.32 million, or EUR 0.15.
“We are pleased to report that Defibrotide product sales increased 25% compared with the prior-year period,” Salvatore Calabrese, senior vice president and CFO of Gentium stated in the press release. “Additionally, we have continued to be cash flow positive and profitable during the first half of 2011, and have decreased our long-term debt while investing in the establishment of our European sales infrastructure. We confirm our previously reported projection that Defibrotide product sales for 2011 are expected to increase 25%-30% over 2010, but due in large part to lower API revenues, we are revising our 2011 product sales forecast to be in the range of EUR 21-23 million instead of EUR 23–25 million as originally projected.”
D. Medical Industries Ltd. (DMED) Announces Issuance of U.S. Patent No. 8,021,334 for Insulin Administration
D. Medical Industries Ltd., a medical device company focused on the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced earlier today that it has been granted U.S. Patent No. 8,021,334, entitled “Drug Delivery Device and Method.”
This patent protects innovative valve technology that allows safe and reliable administration of a desired amount of insulin. In addition to other features, the technology is able to detect malfunctions that could lead to over or under administration. According to the press release, it’s an essential part of D. Medical’s proprietary Intellispring™ and Total Line Control™ systems, which are at the heart of its “Spring™ Zone” and “Spring™ Hybrid” insulin pumps.
Hezkiah Tsoory, D. Medical’s Chief Operating Officer, stated, “As we continue to work toward the commercialization of our Spring pump technology, it is important that the many innovations that define these products are well protected. This U.S. patent issuance serves to strengthen D. Medical’s already formidable intellectual property estate.”
D. Medical’s spring-based delivery mechanism is believed to be a cost-effective alternative to the motor and gear train mechanisms that drive competitive insulin pumps and also enables certain advantageous functions and design features. The company has developed an infusion set for insulin pumps and is focusing its research and development efforts on the development of next generation insulin pumps and a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch.
For more information on D. Medical, please visit www.dmedicalindustries.com
Energy Conversion Devices, Inc. (ENER) Products Used to Power One of the Largest Residential Solar Installations in the World
United Solar, a wholly owned subsidiary of Energy Conversion Devices, Inc. and leading global manufacturer of UNI-SOLAR(R) light-weight, flexible thin-film solar modules, announced before the opening bell today that its UNI-SOLAR brand photovoltaics have been used for one of the largest known residential solar installations in the world. Investors cheered this news as reflected by the 11.11% gain in share price and 1.1+ million volume.
Installed in Chatsworth, California at the residence of Mr. Carl Harberger, a well-regarded sustainable building designer, the solar panels will power lighting, electronics and heating and air conditioning systems. United Solar provided 259 UNI-SOLAR brand flexible, lightweight photovoltaic modules for the 24 kilowatt (kW) solar installation. California-based solar installation company ADR Solar Solutions, Inc. completed the project.
“ADR Solar Solutions, Inc. have designed and installed commercial and residential solar systems for the last seventeen years. We are thrilled to have added to our achievements the UNI-SOLAR installation in Chatsworth, Ca, making it one of the world’s largest residential installations,” stated Ms. Nancy Palmer, ADR’s Manager of Sales and Marketing. “UNI-SOLAR was the only application considered for this installation and is not only working as anticipated, but is a beautiful addition to the design of this state of the art home. ADR Solar Solutions, Inc. will use UNI-SOLAR on many upcoming projects with confidence and look forward to a rock solid relationship.”
According to today’s press release, Mr. Harberger chose UNI-SOLAR panels because of the many unique features of the product. Flexibility was noted specifically as it allowed a perfect fit on the curved rooftop surface. Mr. Harberger took advantage of the rebates offered by the Los Angeles Department of Water & Power as well as U.S. federal tax credits.
“United Solar is proud to be chosen for this opportunity, providing enough solar energy to power Mr. Harberger’s nearly 6,000 square foot home. This is a perfect example of how UNI-SOLAR lightweight solar laminates can be integrated directly into a residence for a cost-saving and renewable energy solution,” said Steve Szamocki, Senior Vice President of Sales-Americas of United Solar.
ShoreTel (SHOR) Partners with Tech Data Canada to Extend Market Reach, Meet Demand
ShoreTel, a leading provider of IP phone systems, announced it has inked a new distribution agreement with Tech Data Canada, the Canadian subsidiary of Tech Data Corporation.
Tech Data Canada specializes in IP telephony, wireless networking and VoIP technologies, and has established a partner base of more than 5,000 technology resellers and solution providers. By partnering with Tech Data Canada, ShoreTel can offer resellers the ability to operate in local currencies and time zones with local inventory, ShoreTel products, and multi-vendor solutions.
The agreement also increases the availability of ShoreTel business communications solutions throughout Canada.
“Demand is high for an affordable, scalable business communications solution that is easy to deploy and will support an increasingly mobile workforce. We’re thrilled to work with Tech Data Canada to deliver ShoreTel’s brilliantly simple line of UC products throughout the Canadian market, and we are confident that the relationship will empower our partners and customers to find the ShoreTel solution best suited to their unique communications needs and resources,” George Pappas, country manager, Canada, ShoreTel, stated in the press release.
The partnership supports ShoreTel’s recently announced global two-tier channel distribution strategy, and Brian Gendron, general manager, Black Box Canada, said the partnership delivers an effective business opportunity for Black Box, as well as ShoreTel and Tech Data Canada.
“We’re pleased with the recent announcement from ShoreTel to enter into two-tier distribution for their industry leading Unified Communications and Mobility Solutions. This creates a highly efficient route to market for Black Box Network Services and our ShoreTel customers through Tech Data’s best in class logistics coupled with industry-leading e-business and IT tools,” Gendron stated in the press release. “We believe Tech Data’s superior capabilities and their attention to detail will help Black Box Network Services continue to meet and exceed the expectations of our enterprise customers. Black Box Network Services Canada is happy to be partnered with ShoreTel and Tech Data, both strong partners to help delight our customers and grow our Canadian business.”
For more information visit www.shoretel.com
Their team requested the the right to publish the content on the MediMISE website. As many of the investors and others interested in this company already know, VistaGen's technology platform has exciting potential and media outlets are intrigued by its implications.
Natus Medical Inc. (BABY) Acquires Embla to Become Worldwide Leader in Sleep Apnea Diagnostics
Natus Medical, a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders, recently announced the acquisition of Embla Systems, the largest company focused solely on sleep diagnostics. Since the mid-1990's, Elma Systems has been developing innovative products to assist sleep labs in the diagnosis of sleep apnea, a sleep disorder that causes abnormally low breathing during sleep. Internationally, Embla is also the leader in devices used for sleep studies in patient’s homes. Embla reported earnings of approximately $30 million for its fiscal year that ended in December 2010.
Natus acquired the shares of Embla for $16.1 million in cash and expects the acquisition will be accretive to earnings in 2012, adding $0.08 to the non-GAAP earnings per share for the year. Natus funded the acquisition with available cash on hand. The company expects that the new company will make Natus number one in the worldwide sleep diagnostic market with annual revenue approaching $35 million.
“Additionally, with approximately 40% of Embla’s revenue coming from international markets, this acquisition positions Natus as the leader in sleep diagnostics outside the United States,” said Jim Hawkins, Chief Executive Officer, Natus in a press release on Friday. “More than 100 million people worldwide are suspected to have obstructive sleep apnea. Because of lack of awareness among both patients and physicians more than 80% of those affected remain undiagnosed.”
In the United States, one in every 15 American is affected by some form of sleep apnea. One study showed that 9% of women and 24% of men has undiagnosed and untreated sleep apnea, and thus were in jeopardy of having coronary artery disease, congestive heart failure, hypertension, pulmonary hypertension, stroke and clinical depression.
Embla partners with sleep businesses to provide sleep sensors and products like the Embletta Gold portable sleep testing device, the Enterprise Sleep Business Management System and three PSG or sleep study platforms which provide tools to optimize the efficiency of sleep labs. Embla has offices in Denver and Buffalo as well as worldwide in Canada, the Netherlands and Germany.
More Information on Natus, Medical can be found at www.natus.com
Pansoft Company Ltd. (PSOF) Strengthens Position in Thriving Chinese Hydrocarbon Sector with Acquisition of Top Coal Mining HR Solutions and Service Provider
Pansoft Company, one of China’s top hydrocarbon industry providers of comprehensive enterprise resource planning software solutions and various professional services, announced a further expansion move recently with the signing of a definitive agreement to acquire Hefei Langji Technology Co., Ltd. (including wholly-owned subsidiary Shanghai Zhongrui) for a reported $1.69M (RMB10.8M).
Chairman of PSOF, Hugh Wang, called the Langji move a milestone for the Company, as it follows the ITLamp Technology and HongAo Power acquisitions of 2010, cementing PSOF in the heart of China’s roaring hydrocarbon sector.
Langji has risen from is start eight years ago to become the Chinese coal-mining industry’s top HR solutions provider. The big, state-owned coal mining groups which make up much of the industry in China have come to rely on the sophisticated HR management solutions Langji is known for. With a staff of some 40 people, Langji pulled down audited revenue of $1M in 2010 ($0.26M net income) and did brisk business through its Shanghai subsidiary, Zhongrui (which will be maintained to focus on small, to mid-sized companies in parallel industries).
Wang noted the solid footprint Langji has in the coal sector and spoke of the respect its HR solutions have won across the spectrum of clients, touting the significance of the acquisition for boosting PSOF’s already commanding penetration into the Chinese hydrocarbon industry as a whole. Wang asserted that the ability to leverage Langji’s customer base, in order to expand the Company’s footprint in the coal mining sector, in conjunction with the core proprietary technologies acquired (like HR solutions engineered specifically for the coal mining industry), would also accelerate the expansion process.
The service/solution platform thus realized certainly will be second-to-none and Pansoft will be able to exploit the Zhongrui Shanghai office to fully target the abundance of this heavily industrial region. It really looks like Pansoft is making all the right moves in order to dominate significant territory in the Chinese hydrocarbon area.
Terms of the deal call for four installments, the first of which (35% of the total) is to be paid in combined cash and PSOF common stock, with the remaining installments paid annually over three years via the same combination of cash and stock (all payments subject to the achievement of revenue targets by the acquired entities). Part of the consideration for the deal will be paid via Pansoft’s share repurchasing activities on the open market (157k shares purchased as of Sept. 15, 2011), as approved by the Company’s board (in accordance with Rule 10b5-18).
Wang emphasized that this important strategic move by the Company would offer an ideal position for long-term growth in the next logical area, coal mining. Calling Langji an excellent fit for the Company’s existing competencies/structure, and pledged an expedient integration into the overall company architecture.
The Life Saving Potential of VistaGen Therapeutics, Inc. (VSTA)
The good news is that new pharmaceutical discoveries are being made nearly every day for the treatment of life threatening diseases. The bad news is that, after hundreds of millions of dollars spent to identify and develop these potential lifesavers, they often never make it to market. Lives may hang in the balance, but it makes little difference when promising new drugs are allowed to sit on the shelf, sometimes indefinitely.
The problem is that every new drug, regardless of its potential efficacy, requires formal approval by the U.S. Food & Drug Administration. Unfortunately, over the past decade, the number of new drugs approved by the FDA has dropped by a full 50%, despite major increases in research and development by the pharmaceuticals. It’s not unusual for a company to invest more than a billion dollars, and over a decade of skilled resources, to get a new drug candidate to market. The fact is that even the most promising candidates can be shelved late in the game, long after the money and time has been spent, due to toxicity issues that were not discovered earlier. It’s a huge loss to the developing company, but a greater loss to the people whose lives could have been improved or even saved.
This is not an isolated problem. It is estimated that approximately a third of all potential new drug candidates fail to meet safety requirements in preclinical or clinical trials. The result is a massive inventory of promising drugs that are currently discontinued due to safety concerns. However, with more predictive toxicology bioassay systems, many of these hibernating drug candidates could be revised and developed, creating variants which are as effective as the original, but without the safety concerns.
VistaGen Therapeutics, Inc. provides an advanced stem-cell based biotechnology that fills that critical gap, allowing shelved drugs to be rescued and moved forward to realize their originally intended potential. The technology offers a significantly improved bioassay option for faster and less expensive drug evaluation and development, including the development of shelved drug variants. VistaGen is clear in its intention to develop a diverse drug pipeline including proprietary drug rescue variants, offering the efficacy of the original, without the toxicity issues.
It represents the possibility of unlocking billions of dollars in drug potential, currently on hold because of a lack of such technology. More importantly to many, it means the chance for rescued lives. As one VistaGen investor put it: “We are very proud to be investing in technology that holds promise for so many.”
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR:
Scorpex, Inc. (SRPX) to Grow with Mexico’s Rising Economy
Scorpex, Inc. has linked its future to Mexico and the country’s increasing importance to the United States. Scorpex is a developing company, positioning itself as a critical provider of industrial and hazardous waste handling services for the growing Baja Mexico/California region. The expanding need for waste processing in the area is made clear by the reception the fledgling company is receiving, both from the government and regional industry. The company is currently finishing its first facility near Ensenada, Baja, Mexico, and already has more business available than it can handle. Once all of the state-of-the-art processing equipment is installed and operational, and final permits are in hand, the company expects to be able to process roughly 800 tons of waste per day.
As Mexico continues to build its economic importance to the U.S., Scorpex is in line to benefit from the growing demand for adequate handling of industrial wastes brought on by increased manufacturing, export, and distribution traffic. The relatively strong recent growth of Mexican industrial output, from auto manufacturing and other areas, in spite of the current state of the American economy, is surprising to some, since the vast majority of Mexico’s exports head north to the U.S. As a buffer against any future negative impact, Mexico’s central bank is expected by some to maintain growth by reducing interest rates. Official forecasts now call for a 3.5% economic growth in 2012. Mexico’s Secretary of Finance, Ernesto Cordero, stated the most basic goal of the government’s economic strategy: “Mexico needs to keep growing and distance itself from fiscal crises in other countries.”
For Scorpex, an important development in U.S.-Mexican economic relations was the recent agreement between the two countries to remove restrictions on trucks using each other’s highways. It was a major sticking point associated with the North American Free Trade Agreement, and its resolution brings the end of high Mexican tariffs, and should stimulate growth on both sides of the border. Besides direct benefits to Scorpex, and the truck traffic it involves, there are more general long-term benefits. As industrial and other business activity rises, the need for what Scorpex offers, already very high, will no doubt increase.
For additional information on Scorpex, visit the company’s website at www.Scorpex.com
SRPX to Grow with Mexico’s Rising Economy
Scorpex, Inc. has linked its future to Mexico and the country’s increasing importance to the United States. Scorpex is a developing company, positioning itself as a critical provider of industrial and hazardous waste handling services for the growing Baja Mexico/California region. The expanding need for waste processing in the area is made clear by the reception the fledgling company is receiving, both from the government and regional industry. The company is currently finishing its first facility near Ensenada, Baja, Mexico, and already has more business available than it can handle. Once all of the state-of-the-art processing equipment is installed and operational, and final permits are in hand, the company expects to be able to process roughly 800 tons of waste per day.
As Mexico continues to build its economic importance to the U.S., Scorpex is in line to benefit from the growing demand for adequate handling of industrial wastes brought on by increased manufacturing, export, and distribution traffic. The relatively strong recent growth of Mexican industrial output, from auto manufacturing and other areas, in spite of the current state of the American economy, is surprising to some, since the vast majority of Mexico’s exports head north to the U.S. As a buffer against any future negative impact, Mexico’s central bank is expected by some to maintain growth by reducing interest rates. Official forecasts now call for a 3.5% economic growth in 2012. Mexico’s Secretary of Finance, Ernesto Cordero, stated the most basic goal of the government’s economic strategy: “Mexico needs to keep growing and distance itself from fiscal crises in other countries.”
For Scorpex, an important development in U.S.-Mexican economic relations was the recent agreement between the two countries to remove restrictions on trucks using each other’s highways. It was a major sticking point associated with the North American Free Trade Agreement, and its resolution brings the end of high Mexican tariffs, and should stimulate growth on both sides of the border. Besides direct benefits to Scorpex, and the truck traffic it involves, there are more general long-term benefits. As industrial and other business activity rises, the need for what Scorpex offers, already very high, will no doubt increase.
For additional information on Scorpex, visit the company’s website at www.Scorpex.com
Scorpex, Inc. (SRPX) to Grow with Mexico’s Rising Economy
Scorpex, Inc. has linked its future to Mexico and the country’s increasing importance to the United States. Scorpex is a developing company, positioning itself as a critical provider of industrial and hazardous waste handling services for the growing Baja Mexico/California region. The expanding need for waste processing in the area is made clear by the reception the fledgling company is receiving, both from the government and regional industry. The company is currently finishing its first facility near Ensenada, Baja, Mexico, and already has more business available than it can handle. Once all of the state-of-the-art processing equipment is installed and operational, and final permits are in hand, the company expects to be able to process roughly 800 tons of waste per day.
As Mexico continues to build its economic importance to the U.S., Scorpex is in line to benefit from the growing demand for adequate handling of industrial wastes brought on by increased manufacturing, export, and distribution traffic. The relatively strong recent growth of Mexican industrial output, from auto manufacturing and other areas, in spite of the current state of the American economy, is surprising to some, since the vast majority of Mexico’s exports head north to the U.S. As a buffer against any future negative impact, Mexico’s central bank is expected by some to maintain growth by reducing interest rates. Official forecasts now call for a 3.5% economic growth in 2012. Mexico’s Secretary of Finance, Ernesto Cordero, stated the most basic goal of the government’s economic strategy: “Mexico needs to keep growing and distance itself from fiscal crises in other countries.”
For Scorpex, an important development in U.S.-Mexican economic relations was the recent agreement between the two countries to remove restrictions on trucks using each other’s highways. It was a major sticking point associated with the North American Free Trade Agreement, and its resolution brings the end of high Mexican tariffs, and should stimulate growth on both sides of the border. Besides direct benefits to Scorpex, and the truck traffic it involves, there are more general long-term benefits. As industrial and other business activity rises, the need for what Scorpex offers, already very high, will no doubt increase.
For additional information on Scorpex, visit the company’s website at www.Scorpex.com
The Life Saving Potential of VistaGen Therapeutics, Inc. (VSTA)
The good news is that new pharmaceutical discoveries are being made nearly every day for the treatment of life threatening diseases. The bad news is that, after hundreds of millions of dollars spent to identify and develop these potential lifesavers, they often never make it to market. Lives may hang in the balance, but it makes little difference when promising new drugs are allowed to sit on the shelf, sometimes indefinitely.
The problem is that every new drug, regardless of its potential efficacy, requires formal approval by the U.S. Food & Drug Administration. Unfortunately, over the past decade, the number of new drugs approved by the FDA has dropped by a full 50%, despite major increases in research and development by the pharmaceuticals. It’s not unusual for a company to invest more than a billion dollars, and over a decade of skilled resources, to get a new drug candidate to market. The fact is that even the most promising candidates can be shelved late in the game, long after the money and time has been spent, due to toxicity issues that were not discovered earlier. It’s a huge loss to the developing company, but a greater loss to the people whose lives could have been improved or even saved.
This is not an isolated problem. It is estimated that approximately a third of all potential new drug candidates fail to meet safety requirements in preclinical or clinical trials. The result is a massive inventory of promising drugs that are currently discontinued due to safety concerns. However, with more predictive toxicology bioassay systems, many of these hibernating drug candidates could be revised and developed, creating variants which are as effective as the original, but without the safety concerns.
VistaGen Therapeutics, Inc. provides an advanced stem-cell based biotechnology that fills that critical gap, allowing shelved drugs to be rescued and moved forward to realize their originally intended potential. The technology offers a significantly improved bioassay option for faster and less expensive drug evaluation and development, including the development of shelved drug variants. VistaGen is clear in its intention to develop a diverse drug pipeline including proprietary drug rescue variants, offering the efficacy of the original, without the toxicity issues.
It represents the possibility of unlocking billions of dollars in drug potential, currently on hold because of a lack of such technology. More importantly to many, it means the chance for rescued lives. As one VistaGen investor put it: “We are very proud to be investing in technology that holds promise for so many.”
The Life Saving Potential of VistaGen Therapeutics, Inc. (VSTA)
The good news is that new pharmaceutical discoveries are being made nearly every day for the treatment of life threatening diseases. The bad news is that, after hundreds of millions of dollars spent to identify and develop these potential lifesavers, they often never make it to market. Lives may hang in the balance, but it makes little difference when promising new drugs are allowed to sit on the shelf, sometimes indefinitely.
The problem is that every new drug, regardless of its potential efficacy, requires formal approval by the U.S. Food & Drug Administration. Unfortunately, over the past decade, the number of new drugs approved by the FDA has dropped by a full 50%, despite major increases in research and development by the pharmaceuticals. It’s not unusual for a company to invest more than a billion dollars, and over a decade of skilled resources, to get a new drug candidate to market. The fact is that even the most promising candidates can be shelved late in the game, long after the money and time has been spent, due to toxicity issues that were not discovered earlier. It’s a huge loss to the developing company, but a greater loss to the people whose lives could have been improved or even saved.
This is not an isolated problem. It is estimated that approximately a third of all potential new drug candidates fail to meet safety requirements in preclinical or clinical trials. The result is a massive inventory of promising drugs that are currently discontinued due to safety concerns. However, with more predictive toxicology bioassay systems, many of these hibernating drug candidates could be revised and developed, creating variants which are as effective as the original, but without the safety concerns.
VistaGen Therapeutics, Inc. provides an advanced stem-cell based biotechnology that fills that critical gap, allowing shelved drugs to be rescued and moved forward to realize their originally intended potential. The technology offers a significantly improved bioassay option for faster and less expensive drug evaluation and development, including the development of shelved drug variants. VistaGen is clear in its intention to develop a diverse drug pipeline including proprietary drug rescue variants, offering the efficacy of the original, without the toxicity issues.
It represents the possibility of unlocking billions of dollars in drug potential, currently on hold because of a lack of such technology. More importantly to many, it means the chance for rescued lives. As one VistaGen investor put it: “We are very proud to be investing in technology that holds promise for so many.”
Article posted on Medimise.com
VistaGen Therapeutics, Inc. (VSTA) Stem Cell Technology to Test New Drugs for Toxicity Before Humans Trials
http://www.medimise.com/news/vistagen-therapeutics-inc-vsta-stem-cell-technology-to-test-new-drugs-for-toxicity-before-humans-trials
Asia Pacific Wire & Cable (APWC) Reports Solid Q2, HY 2011 Results
Asia Pacific Wire & Cable, manufacturer of telecommunications products in the Asia Pacific region, today reported strong, unaudited consolidated results for the second quarter and first half ended June 30, 2011.
For the second quarter of 2011, APWC reported revenues of $148.7 million, up 40 percent compared to $106.0 million reported in the comparable quarter of 2010.
Gross profit increased 15 percent to $16.4 million compared to $14.2 million reported in the second quarter of 2010.
The company reported net income attributable to APWC shareholders at $2.4 million, or $0.17 per share, compared with $3.7 million, or $0.27 per share, in the same period a year ago.
Operating income decreased 1.6 percent to $6.8 million compared to the $7.0 million reported in the year-ago quarter.
For the first half of 2011, APWC reported revenues of $270.5 million, a 28 percent increase over the first six months of 2010.
Gross profit was $29.3 million in the first half, up 14 percent from $25.6 million reported in the first half of last year.
Operating income in the first half increased 4.5 percent to $12.7 million compared to $12.2 million in the year-ago period.
The company reported net income attributable to APWC shareholders for the first half of 2011 was $5.1 million, or $0.37 per share, compared to $7.4 million, or $0.54 per share, in the year-ago period.
As of June 30, 2011, APWC reported $75.5 million in cash and cash equivalents, and $1.0 million in unrestricted short-term bank deposits, totaling $76.5 million, compared to cash and equivalents of $63.2 million as of December 31, 2010. The company reported total current assets of $370.2 million as of June 30, 2011, compared to $329.5 million at the end of 2010; total current liabilities were $191.2 million as of June 30, 2011, compared to $158.8 million at the end of 2010.
For more information visit www.apwcc.com